#United States #Miami #spinal fusion #Vivex Biologics #VIA Form+

Vivex Biologics Introduces Breakthrough Findings in Spinal Fusion Research

Vivex Biologics, Inc., a trailblazer in medical technology renowned for its innovative allografts, has made headlines with a new peer-reviewed study that highlights the long-term success of its VIA Form+™ cryopreserved viable bone allograft. Published in the esteemed Journal of Spine Neurosurgery, this research explores the clinical efficacy and radiographic results of lumbar interbody fusion (LIF) surgeries utilizing this cutting-edge product.

Study Overview and Methodology

The publication details insights gleaned from a cohort of 14 patients who underwent LIF procedures between January 2022 and March 2025. These patients received single- or two-level fusions, employing VIA Form+ as a sole bone graft substitute—eliminating the need for autografts or additional materials. VIA Form+ comprises a specialized cellular bone matrix (CBM), utilizing a 100% tissue scaffold made from demineralized cortical bone fibers and enriched with cancellous chips that contain endogenous bone cells. This unique composition facilitates an optimal environment for osteogenesis while ensuring excellent usability through its syringe packaging.

Key Findings from the Research

The results of the study showcase several remarkable outcomes:
1. Radiographic Fusion Success: An impressive 100% of patients achieved successful radiographic fusion within six months post-surgery. There was no evidence of implant migration, subsidence, or loss of segmental lordosis throughout the follow-up period.
2. Sustained Clinical Improvement: Participants reported significant reductions in back and leg pain symptoms, coupled with the maintenance of neurological function.
3. No Adverse Events: Throughout the study duration, there were zero complications attributed to the CBM allograft, further emphasizing its safety in clinical settings.

Rey Pascual, Co-President of Vivex, remarked, "This long-term follow-up provides important clinical evidence supporting the sustained effectiveness of VIA Form+ as a stand-alone cellular bone matrix. The absence of fusion deterioration, implant complications, or reoperations over three years reinforces the role of advanced CBMs in spinal fusion procedures, including in higher-risk patient populations."

Clinical Implications

The study highlights the significant advantages of using cryopreserved viable bone allografts like VIA Form+ over traditional autologous iliac crest bone grafts, which typically carry risks of donor site complications and require additional surgeries. As noted by orthopedic surgeon and co-author, Dr. John Kenneth Burkus, “The long-term results demonstrate that this innovative approach can provide consistent and reliable outcomes, even in patients with comorbidities such as smoking, diabetes, and obesity.”

Although the study acknowledges limitations, including its retrospective design and small participant pool, it nonetheless lays the groundwork for further exploration of cellular bone allografts in spinal procedures.

Conclusion

Vivex Biologics continues to stand at the forefront of medical innovation, focusing on therapies that enhance healing and recovery for patients experiencing musculoskeletal issues. The promising outcomes presented in this study not only reinforce the potential of VIA Form+ but also pave the way for future advancements in spinal surgery techniques. For additional information on Vivex Biologics and their innovative healthcare solutions, please visit www.vivex.com.